Introduction
============

The increasing brain GABA (gamma-amino butyric acid) content and administration of centrally active GABA-mimetic agents have been used as an effective therapeutic approach for the treatment of epilepsy ([@b36]). However, it has also been suggested that the use of drugs that continually alter synaptic transmission does not represent the best strategy to control seizure expression ([@b13]). Prolonged administration of drugs enhancing GABA action can lead to reduced GABAergic function ([@b19]) and alterations in GABA~A~ receptors ([@b9]; [@b59]) as well as tolerance and dependence, especially to sedative and anticonvulsant effects of drugs such as benzodiazepines (BDZ) ([@b7]).

The increase of GABAergic transmission can induce excitatory effects ([@b13]). Chronic administration of BDZ can produce decreased sensitivity to GABA ([@b14]) and reduced ability of this amino acid to enhance BDZ binding ([@b8]). Indeed, withdrawal symptoms or spontaneous seizures have been reported to occur in nonepileptic BDZ abusers upon drug discontinuation ([@b34]).

The present study was designed to determine the effects of subchronic pretreatment with drugs enhancing GABAergic transmission on pentylenetetrazol (PTZ)-induced seizures and their correlation with BDZ receptor binding. We used vigabatrin, gabapentin, and diazepam because these are antiepileptic compounds activating the GABAergic system. Vigabatrin is a GABA structural analogue, which irreversibly blocks GABA transaminase (GABA-T), the enzyme responsible of GABA degradation ([@b27]; [@b42]). The mechanisms of action of gabapentin, an analogue of GABA ([@b44]), appear to be a complex synergy between increased GABA synthesis and function ([@b45]), non-NMDA receptor antagonism and binding to the α2δ-subunit of voltage dependent calcium channels. The latter action inhibits the release of excitatory neurotransmitters ([@b5]). Diazepam, as a BDZ agonist, increases the channel opening frequency in presence of GABA increasing the effects of this amino acid ([@b22]). Autoradiography studies using \[^3^H\]flunitrazepam were carried out to evaluate BDZ receptor binding in specific brain areas of mice treated subchronically with these antiepileptic drugs.

Material and methods
====================

Animals
-------

The experimental subjects were adult male CD-1 mice, weighing 25--30 g at the beginning of the experiments. Animals were housed in groups of 5--6 per cage (24 × 17 × 12 cm) under controlled environmental conditions (22 ± 1 °C; 12; 12-h light--dark cycle, lighting at 8:00 h; food and water ad libitum). Experimental procedures were conducted according to the Mexican Official Standard NOM-062-ZOO-1999 and the Ethical Committee of the Center for Research and Advanced Studies (Mexico, Project 222/04).

Evaluation of PTZ-induced seizures
----------------------------------

Mice received a daily administration of saline (0.1 ml/10 g, per oral \[po\] or intraperitoneal \[ip\]) for 1 week. This procedure allows the animals to habituate to manipulation, avoiding downregulation of BDZ binding induced by acute handling ([@b3]). Thereafter, they were daily treated with vigabatrin (500 mg/kg po, n = 10), gabapentin (100 mg/kg po, n = 10), or diazepm (10 mg/kg ip, n = 10) for 8 days. Immediately after each drug administration, animals were kept in individual cages for 30 min for behavioral evaluation. Preliminary experiments from our group indicated that a single administration of diazepam, gabapentin, or vigabatrin, at the doses and routes described above, was able to reduce PTZ-induced seizures and Fos expression in the mouse brain. For the present study, we chose the oral route for gabapentin and vigabatrin administration because it is how these drugs are used in patients. Indeed, vigabatrin exerts similar anticonvulsant potency at oral and ip administration ([@b32]). A solution of PTZ (Sigma Aldrich Ltd., St. Louis, MO, USA) freshly prepared was applied (90 mg/kg, ip) 24 h after the last drug administration. Latencies to the first clonic seizure, tonic extension, and convulsion-induced death were evaluated during 30 min. The criterion of death was considered when animals spent 1 min or more with breathing and heart arrest. For each experimental drug, one control group (n = 10) was monitored in parallel. Control animals were manipulated as described above, except that they received daily saline administration instead of antiepileptic drugs. Diazepam was dissolved in vehicle (0.5% Tween 80 and saline), whereas gabapentin, vigabatrin, and PTZ were dissolved in saline.

Evaluation of \[^3^H\]flunitrazepam binding
-------------------------------------------

After daily injection of saline (0.1 ml/10 g, po or ip) for 1 week, mice received daily administration with vigabatrin, gabapentin, or diazepam for 8 days, at the doses and routes described above (n = 10 per drug). For each drug, a control group (n = 10) was monitored in parallel, in which animals received saline instead of antiepileptic drugs. Mice were sacrificed by decapitation 24 h after the last administration and their brains were quickly removed, frozen in pulverized dry ice and stored at −70 °C. Frozen coronal sections of 20 μm were cut in a cryostat, thaw-mounted on gelatin-coated slides, and stored at −70 °C until the day of incubation.

Tris-HCl buffer (170 mM, pH 7.4) was used. Initially, brain sections were prewashed for 30 min at 25 °C. Then, brain sections were incubated during 45 min at 4 °C in a 2 nM \[^3^H\]flunitrazepam solution (88 Ci/mmol), in absence or presence of 1 μM of chlordiazepoxide. Binding obtained in presence of chlordiazepoxide was considered non-specific. Incubation was completed with 2 consecutive washes (1 min each) and a distilled water rinse (2 s) at 4 °C. The sections were then quickly dried under a gentle stream of cold air.

Slides were arrayed in X-ray cassettes with tritium standards (Amersham Biosciences, Piscataway, NJ, USA) and apposed to tritium-sensitive film (Amersham Ultrafilm) for 3 weeks at room temperature. Films were developed using standard Kodak D11 and fixer. Optical densities were determined using a video-computer enhancement program (JAVA Jandel Video Analysis Software; Jandel Scientific, Corte. Madera, CA, USA). Brain regions were localized by reference to the mouse brain atlas of [@b53]. For each structure, 10 optical density readings were taken from at least 5 sections and they were averaged. The optical density readings of the standards were used to determine tissue radioactivity values (dpm/mm^2^) for the accompanying tissue sections. Then, dpm/mm^2^ values were converted to fmol/mg protein by dividing dpm by the specific activity of \[^3^H\]flunitrazepam (88 Ci/mmol) by 2.22. The value 2.22 represents the conversion factor from Ci to dpm.

\[^3^H\]flunitrazepam binding was analyzed in the following structures: motor, sensorimotor, and cingulate cortices; caudate putamen, nucleus accumbens, dentate gyrus, and CA1--3 fields of hippocampus; medial, and basolateral amygdala nuclei; complete thalamus and hypothalamus.

Statistical analysis
--------------------

The values obtained from PTZ-induced seizures and receptor binding were examined statistically by Student's *t* tests.

Results
=======

Saline group
------------

All control animals (100%) pretreated with saline presented clonic seizures, and tonic extension after PTZ administration. The incidence of death was from 60% to 80%. Latencies (mean ± SD) for these PTZ-induced changes were as follows: clonic seizures, 50 ± 4 s; tonic extension, 527 ± 86 s; death, 636 ± 74 s ([Figure 1](#fig1){ref-type="fig"}). Concerning BDZ binding, \[^3^H\]flunitrazepam binding was robust throughout the following evaluated brain areas: motor, sensorimotor, and cingulate cortices, dentate gyrus, CA1--3 fields of hippocampus, medial, and basolateral amygdala nuclei. \[^3^H\]flunitrazepam binding was mild to moderate at the level of caudate putamen, nucleus acumbens, thalamus and hypothalamus ([Tables 1](#tbl1){ref-type="table"}-[3](#tbl3){ref-type="table"}).

![Effects of subchronic administration with diazepam (upper panel), vigabatrin (medium panel) and gabapentin (lower panel) on PTZ-induced convulsions. Results show the latency in seconds from the injection of PTZ (90 mg/kg ip) to first clonus, tonic extension and death.\
**Note:** \*p \< 0.05 when compared with control group.](ndt0403-619-01){#fig1}

###### 

\[^3^H\]Flunitrazepam binding (fmol/mg of protein) in brain areas of mice treated with subchronic administration of saline and diazepam (10 mg/kg ip)

  Brain area             Saline         Diazepam
  ---------------------- -------------- -----------------------------------------------
  Motor cortex           524.7 ± 27.5   382.6 ± 61.0[\*](#tf1-2){ref-type="table-fn"}
  Sensorimotor cortex    503.4 ± 35.2   367.6 ± 62.4[\*](#tf1-2){ref-type="table-fn"}
  Cingulate cortex       542.1 ± 30.1   334.4 ± 50.0[\*](#tf1-2){ref-type="table-fn"}
  Caudate putamen        199.2 ± 40.0   143.7 ± 8.4
  Nucleus accumbens      253.8 ± 38.1   210.9 ± 34.9
  CA1--CA3 fields        435.7 ± 57.1   286.1 ± 47.7[\*](#tf1-2){ref-type="table-fn"}
  Dentate gyrus          564.3 ± 62.1   378.5 ± 69.4[\*](#tf1-2){ref-type="table-fn"}
  Medial amygdala        552.7 ± 50.2   322.8 ± 56.6[\*](#tf1-2){ref-type="table-fn"}
  Basolateral amygdala   466.3 ± 60.6   276.3 ± 56.8[\*](#tf1-2){ref-type="table-fn"}
  Thalamus               290.6 ± 37.7   206.8 ± 34.7
  Hypothalamus           431.5 ± 53.4   280.3 ± 57.3[\*](#tf1-2){ref-type="table-fn"}

**Notes:** Each value represents the mean ± standard error;

p \< 0.05 compared with the saline group.

###### 

\[^3^H\]Flunitrazepam binding (fmol/mg of protein) in brain areas of mice treated with subchronic administration of saline and gabapentin (100 mg/kg po)

  **Brain area**         **Saline**     **Gabapentin**
  ---------------------- -------------- ------------------------------------------------
  Motor cortex           505.5 ± 23.2   401.8 ± 30.4[\*](#tf3-2){ref-type="table-fn"}
  Sensorimotor cortex    503.1 ± 29.4   329.1 ± 37.7[\*](#tf3-2){ref-type="table-fn"}
  Cingulate cortex       501.5 ± 53.2   397.2 ± 33.0[\*](#tf3-2){ref-type="table-fn"}
  Caudate putamen        190.4 ± 21.3   173.9 ± 28.4
  Nucleus accumbens      296.5 ± 28.3   218.9 ± 27.9
  CA1--CA3 fields        480.7 ± 12.8   315.3 ± 33.5[\*](#tf3-2){ref-type="table-fn"}
  Dentate gyrus          535.7 ± 18.4   417.7 ± 29.8[\*](#tf3-2){ref-type="table-fn"}
  Medial amygdala        463.9 ± 50.7   338.0 ± 40.7[\*](#tf3-2){ref-type="table-fn"}
  Basolateral amygdala   458.8 ± 15.7   306.3 ± 32.67[\*](#tf3-2){ref-type="table-fn"}
  Thalamus               315.5 ± 55.2   172.6 ± 32.3[\*](#tf3-2){ref-type="table-fn"}
  Hypothalamus           389.1 ± 56.3   238.9 ± 49.6

**Notes:** Each value represents the mean ± standard error;

p \< 0.05 compared with the saline group.

Effects of subchronic administration with diazepam
--------------------------------------------------

Mice pretreated subchronically with diazepam showed reduced latency to the first PTZ-induced clonus (21%, p \< 0.05), tonic extension (27%, p \< 0.05) and death (37%, p \< 0.05) ([Figure 1](#fig1){ref-type="fig"}). Mortality rate was similar to that found in the control group (80%).

Subchronic administration with diazepam induced a significant decrease of \[^3^H\]flunitrazepam binding in motor (25%, p \< 0.05), sensorimotor (27%, p \< 0.05) and cingulate (38%, p \< 0.05) cortices, dentate gyrus (33%, p \< 0.05), and CA1--3 fields of hippocampus (34%, p \< 0.05), medial (41%, p \< 0.05) and basolateral (40%, p \< 0.05) amygdala nuclei, and hypothalamus (35%, p \< 0.05) ([Table 1](#tbl1){ref-type="table"}).

Effects of subchronic administration with vigabatrin
----------------------------------------------------

Animals pretreated subchronically with vigabatrin presented enhanced latency to the first clonus (32%, p \< 0.05), but shorter latencies for tonic extension (55%, p \< 0.05) and death (58%, p \< 0.05) ([Figure 1](#fig1){ref-type="fig"}). Mortality rate was not significantly modified (60%) when compared with control group (70%).

Subchronic administration with vigabatrin tended to decrease \[^3^H\]flunitrazepam binding in motor (10%) and cingulate (6%) cortices; caudate putamen (18%) and nucleus accumbens (11%) ([Table 2](#tbl2){ref-type="table"}).

###### 

\[^3^H\]Flunitrazepam binding (fmol/mg of protein) in brain areas of mice treated with subchronic administration of saline and vigabatrin (500 mg/kg po)

  **Brain area**         **Saline**     **Vigabatrin**
  ---------------------- -------------- ----------------
  Motor cortex           439.7 ± 52.4   398.9 ± 33.8
  Sensorimotor cortex    360.3 ± 50.6   368.9 ± 38.3
  Cingulate cortex       408.5 ± 51.5   386.6 ± 33.6
  Caudate putamen        180.4 ± 21.9   147.4 ± 13.6
  Nucleus accumbens      190.7 ± 26.6   168.6 ± 14.6
  CA1--CA3 fields        292.1 ± 38.7   272.6 ± 23.0
  Dentate gyrus          365.8 ± 43.2   351.5 ± 30.8
  Medial amygdala        354.5 ± 46.2   379.8 ± 31.8
  Basolateral amygdala   288.5 ± 29.4   295.1 ± 34.0
  Thalamus               245.1 ± 31.5   277.8 ± 26.9
  Hypothalamus           296.9 ± 36.4   292.6 ± 24.7

**Notes**: Each value represents the mean ± standard error.

Effects of subchronic administration with gabapentin
----------------------------------------------------

Mice treated subchronically with gabapentin did not show significant changes in latency to the different components of PTZ-induced convulsions ([Figure 1](#fig1){ref-type="fig"}). However, their mortality rate was lower (40%) when compared with control animals (60%).

Subchronic administration with gabapentin reduced \[^3^H\]flunitrazepam binding in the motor (20%, p \< 0.05), sensorimotor (34%, p \< 0.05) and cingulate (20%, p \< 0.05) cortices; dentate gyrus (22%, p \< 0.05) and CA1--CA3 fields of hippocampus (34%, p \< 0.05), medial (27%, p \< 0.05) and basolateral (33%, p \< 0.05) amygdala nuclei, thalamus (45%, p \< 0.05) and hypothalamus (38%, p \< 0.05) ([Table 3](#tbl3){ref-type="table"}).

Discussion
==========

There is growing awareness that antiepileptic drugs can sometimes worsen epileptic disorders ([@b37]) by disrupting the equilibrium between excitatory and inhibitory circuits ([@b28]). In the present study, we found that mice pretreated subchronically with antiepileptic drugs enhancing GABAergic neurotransmission showed an augmented susceptibility to PTZ-induced seizures, reduced BDZ receptor binding, or both. These effects may be associated with a withdrawal-like syndrome as consequence of the sudden cessation of antiepileptic drugs.

PTZ is a noncompetitive GABA receptor antagonist that produces generalized seizures at high doses. The forebrain is involved in the expression of clonic seizures, whereas the activation of brainstem structures participates in the expression of the tonic component ([@b58]). We found that there is an aggravation of PTZ-induced seizures following the repetitive administration of diazepam or vigabatrin. The shorter latency to all the components of the PTZ-induced seizures after subchronic administration with diazepam could result from a higher activation of forebrain areas, while the facilitation of the tonic extension component and mortality after subchronic treatment with vigabatrin could be restricted to an overactivation of brainstem areas. These results support previous studies indicating that the abrupt discontinuation of long-term use of BDZ may produce status epilepticus ([@b16]) and a higher seizure susceptibility to bicuculline ([@b15]). Regarding vigabatrin, its repetitive administration leads to decreased electroconvulsive threshold ([@b29]) and does not prevent the development of secondary spontaneous seizures as consequence of status epilepticus ([@b21]).

Diazepam produces its overt effects by interacting with a specific recognition site on GABA~A~ receptors in the mammalian central nervous system. Diazepam enters brain rapidly, and is also cleared rapidly, yielding desmethyldiazepam and oxazepam as metabolites in plasma and brain ([@b17]). However, the repetitive daily injection of diazepam is associated with a peak concentration at 2 h after injection and a progressive drug accumulation in brain ([@b12]). This situation represents a marked fluctuation in receptor occupancy by diazepam over a 24-h period that may induce a pharmacological kindling effect ([@b4]), a critical condition for the higher susceptibility to PTZ-induced seizures observed in the present study.

The reduction in the BDZ receptor binding detected after the subchronic administration with diazepam is in agreement with the results obtained from other authors in mouse brain ([@b39], [@b40], [@b41]; [@b18]; [@b46]). Chronic treatment with diazepam has been shown to alter GABA~A~ receptor affinity for the agonist GABA and some BDZ binding characteristics ([@b47]; [@b56]). Indeed, repetitive daily injection of diazepam decreases GABA enhancement of BDZ binding ([@b4]). These receptor changes could be involved in the lower BDZ binding and the higher vulnerability to PTZ-induced convulsions detected after the repetitive administration with diazepam.

The pharmacodynamic effects of vigabatrin (inhibition of central and peripheral GABA-T and increase of brain GABA levels) remain after the drug has been eliminated from plasma ([@b6]). However, when treatment is continued for 8 days, more marked effects of vigabatrin on GABA-T and GABA, a more severe toxicity and higher vigabatrin plasma concentrations are observed ([@b48]; [@b49]), and tolerance developed to the anticonvulsant effect of the treatment ([@b32]). We found that the subchronic administration of vigabatrin did not modify the \[^3^H\]flunitrazepam binding, a finding that is in agreement with others authors ([@b20]; [@b23]; [@b50]). Probably, the magnitude of the GABA level increase by vigabatrin is not sufficient to induce changes in the BDZ receptor ([@b35]). However, subcronic treatment with vigabatrin facilitated PTZ-induced seizures, an effect that could be explained by receptor desensitization or toxic effects. Indeed, in vigabatrin-treated animals, diazepam at high doses displayed lower anticonvulsant effects ([@b43]).

Gabapentin was originally developed as a chemical analogue of GABA. However, different mechanisms are known to be involved in different therapeutic actions of this drug ([@b11]). Its mechanisms of action appear to be a complex synergy between increased GABA synthesis, non-NMDA receptor antagonism and binding to the α2δ subunit of voltage dependent calcium channels. The latter action inhibits the release of excitatory neurotransmitters ([@b5]). Gabapentin fails to influence GABA concentrations following both single and repeated administration in mice ([@b26]), but increases aminooxyacetic acid-induced GABA accumulation in several brain regions ([@b30]). The plasma gabapentin half-life after oral administration in rodents is only about 2 h, and there is no evidence for accumulation of active metabolites ([@b51]). Gabapentin exerts potent anticonvulsant effect in rats after 2 h, but this effect is completely lost after 9 h ([@b33]). Our experiments revealed that subchronic administration with gabapentin did not modify the generalized seizures induced by PTZ, suggesting that its repetitive administration does not induce subsequent withdrawal-like effects.

It is known that the chronic exposition of an agonist produces an adaptation response that could be associated with receptor down-regulation or phosphorylation with a subsequent decrease in the response of involved system ([@b2]). These mechanisms could explain the decreased BDZ binding after the repetitive administration of antiepileptic drugs enhancing the GABAergic system. The differential effects on PTZ-induced seizures produced after subchronic diazepam, vigabatrin, and gabapentin may result from changes in specific subunits that regulate the GABA~A~ or BDZ binding. For example, mutations in the γ2 subunit may cause incorrect assembly of subunits with the receptor complex reducing sensitivity to BDZ, which would lead to an increase in neuronal excitability ([@b57]). Similarly, deletion of GABA~A~ receptor α1-subunit alters receptor subtype assembly, pharmacological and behavioral responses to BDZ ([@b25]). Concerning diazepam, its repetitive daily injection increases α1-subunit mRNA levels, an effect that may result in an increase in diazepam insensitive GABA~A~ receptor subtypes ([@b4]). More experiments should be carried out to determine how the repetitive administration of antiepileptic drugs is associated with changes in GABA~A~ receptor subunits leading to facilitation of seizure activity.

The mechanisms underlying the facilitation in seizure activity by antiepileptic drugs are poorly understood, but they may include the unmasking of secondary pharmacodynamic effects at high dosage or an undesired extension of the drug primary action to additional cell populations or neurotransmitters. Studies support the interactions between GABA and cannabinoid systems ([@b38]; [@b52]). In fact, activation of presynaptic cannabinoid type 1 (CB1) receptors induces robust inhibition of local GABAergic afferents or depolarization-induced suppression of inhibition (DSI) ([@b55]; [@b55]). It is possible that the abrupt cessation of GABAergic drugs induces a withdrawal syndrome associated with sensitized GABAergic synapses to the presynaptic effect of cannabinoid CB1 receptor stimulation ([@b10]). This situation may facilitate the DSI and the reduced threshold to the PTZ-induced seizures.

Our results provide evidence of a relationship between subchronic exposition of an antiepileptic drug and the decrease in the BDZ receptor binding, a phenomenon that could be involved in the mechanisms of pharmacoresistant epilepsy ([@b1]; [@b24]; [@b31]).
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